MK 2206 | CAS:1032350-13-2

Chemscene社は、高品質な低分子化合物を提供しているメーカーです。
Chemscene社のMK 2206(CAS:1032350-13-2)をご紹介します。

※本製品は研究用です。研究用以外には使用できません。

Name:MK 2206 dihydrochloride; 
Cat. No. :CS-0002
CAS No. :1032350-13-2
Formula:C25H23Cl2N5O
M. Wt. : 480.39
Solubility:DMSO: 4.8 mg/mL (Need ultrasonic and warming)

MK 2206 is an orally active allosteric Akt inhibitor with IC50 of 5 nM/12 nM/65 nM for Akt1/Akt2/Akt3, respectively.IC50 & Target: IC50: 5 nM/12 nM/65 nM (Akt1/Akt2/Akt3)[1]In Vitro: The NPC cell lines CNE-1, CNE-2, HONE-1, and SUNE-1 are treated with increasing doses of MK-2206 (0-10 μM) for 72 and 96 hours, results in dose- and time-dependent inhibition of cell viability. At 72 and 96 hours, the IC50 values of MK-2206 in CNE-1, CNE-2, and HONE-1 cell lines are 3-5 μM, and in SUNE-1, they are less than 1 μM[1]. MK-2206 alone more potently inhibits the cell growth of Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292; IC50s of 5.5, 4.3, and 5.2 μM, respectively) as compared with Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6; IC50s of 13.5, 14.1, 27.0, and 28.6 μM, respectively), with the exception of NCI-H460, which has a PIK3CA E545K mutation (IC50, 3.4 μM)[2].In Vivo: MK-2206 doses (480 mg/kg once a week and 240 mg/kg three times a week) can inhibit the growth of human CNE-2 xenografts in nude mice. In the two MK-2206 groups, the tumor weights are much lighter than the control group (P[1].

Hirai H, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Therapy, 2010, 9(7), 1956-1967. Zhao YY, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37. Jain A, et al. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. Oncogene. 2017 Aug 10;36(32):4585-4596.